Pancreatic Cancer Research

ResearcherSecond Military Medical UniversityActive in the last 2 years

Lingong Jiang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6214-2069; OpenAlex author ID A5005357118. Sources: OpenAlex.

Their work

Papers
16
Trials
0
Grants
0
Labs led
0
Collaborators
18
Papers, trials and grants by year

2019: 1 paper · 2020: 2 papers · 2021: 4 papers · 2022: 4 papers · 2023: 1 paper · 2024: 2 papers · 2025: 2 papers

Papers 16

  1. ADJUPANC protocol: a phase III study of adjuvant chemotherapy versus chemoradiotherapy for pancreatic cancer. Co-author DOI 10.1080/14796694.2025.2522061↗
  2. Stereotactic body radiation therapy plus adoptive vNKT cell therapy for pancreatic cancer: protocol of a phase II trial. Co-author DOI 10.1080/1750743x.2025.2533112↗
  3. Immune profiling of pancreatic cancer for radiotherapy with immunotherapy and targeted therapy: Biomarker analysis of a randomized phase 2 trial. Co-author DOI 10.1016/j.radonc.2023.109941↗
  4. Stereotactic body radiation therapy for the primary tumor and oligometastases versus the primary tumor alone in patients with metastatic pancreatic cancer. Co-author DOI 10.1186/s13014-024-02493-8↗
  5. Effect of stereotactic body radiotherapy dose escalation plus pembrolizumab and trametinib versus stereotactic body radiotherapy dose escalation plus gemcitabi… Co-author DOI 10.1016/j.eclinm.2022.101764↗
  6. Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer… Co-author DOI 10.1016/s1470-2045(22)00066-3↗
  7. Biologically effective doses of 60-70Gy versus >70Gy of stereotactic body radiotherapy (SBRT) combined with chemotherapy in locally advanced pancreatic cancer:… Co-author DOI 10.1136/bmjopen-2021-049382↗
  8. Uniform expansion vs. non-uniform expansion of gross tumor volume based on recurrence patterns to form planning target volume of stereotactic body radiation th… Co-author DOI 10.21203/rs.3.rs-1919548/v1↗
  9. Dose evaluations of organs at risk and predictions of gastrointestinal toxicity after re-irradiation with stereotactic body radiation therapy for pancreatic ca… Co-author DOI 10.3389/fonc.2022.1021058↗
  10. Stereotactic body radiation therapy with sequential S-1 for patients with locally advanced pancreatic cancer and poor performance status: An open-label, single… Co-author DOI 10.1016/j.radonc.2021.07.009↗
  11. Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer… Co-author DOI 10.1016/s1470-2045(21)00286-2↗
  12. Personalized designs of adjuvant radiotherapy for pancreatic cancer based on molecular profiles. Co-author DOI 10.1111/cas.14486↗
  13. Development and Validation of Multicenter Predictive Nomograms for Locally Advanced Pancreatic Cancer After Chemoradiotherapy. Co-author DOI 10.3389/fonc.2021.688576↗
  14. Regulation of pancreatic cancer microenvironment by an intelligent gemcitabine@nanogel system via in vitro 3D model for promoting therapeutic efficiency. Co-author DOI 10.1016/j.jconrel.2020.06.001↗
  15. Failure patterns and outcomes of dose escalation of stereotactic body radiotherapy for locally advanced pancreatic cancer: a multicenter cohort study. Co-author DOI 10.1177/1758835920977155↗
  16. Prognostic values of 18F-FDG PET/CT metabolic parameters and clinical figures in locally advanced pancreatic cancer underwent chemotherapy combined with stereo… Co-author DOI 10.1097/md.0000000000015064↗

Closest collaborators

The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yangsen Cao · 14 shared papers, 2020–2025 · strength 2.48
  2. Xiaofei Zhu · 15 shared papers, 2019–2025 · strength 2.43
  3. Huojun Zhang · 14 shared papers, 2020–2025 · strength 2.29
  4. Yusheng Ye · 12 shared papers, 2020–2025 · strength 2.06
  5. Wenyu Liu · 8 shared papers, 2021–2025 · strength 1.59
  6. Shuiwang Qing · 3 shared papers, 2020–2021 · strength 0.35
  7. Gang Jin · 2 shared papers, 2021–2022 · strength 0.29
  8. Xiaofei Zhu · 1 shared paper, 2025 · strength 0.25
  9. Ting‐Shi Su · 2 shared papers, 2020–2021 · strength 0.23
  10. Yuxin Shen · 1 shared paper, 2021 · strength 0.13
  11. Xixu Zhu · 1 shared paper, 2021 · strength 0.12
  12. Shengnan Ren · 1 shared paper, 2019 · strength 0.10
  13. Changjing Zuo · 1 shared paper, 2019 · strength 0.10
  14. Anyu Zhang · 1 shared paper, 2019 · strength 0.10
  15. Xiao Li · 1 shared paper, 2019 · strength 0.10
  16. Yuan Yuan Ma · 1 shared paper, 2019 · strength 0.10
  17. Wei Li · 1 shared paper, 2020 · strength 0.09
  18. Di Chen · 1 shared paper, 2020 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.